Literature DB >> 18818704

17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation.

M K Dijkstra, K van Lom, D Tielemans, F Elstrodt, A W Langerak, M B van 't Veer, M Jongen-Lavrencic.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18818704     DOI： 10.1038/leu.2008.264

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  27 in total

1.  Molecular and cellular pathways associated with chromosome 1p deletions during colon carcinogenesis.

Authors:  Claire M Payne; Cheray Crowley-Skillicorn; Carol Bernstein; Hana Holubec; Harris Bernstein
Journal:  Clin Exp Gastroenterol       Date:  2011-05-03

2.  A p53 axis regulates B cell receptor-triggered, innate immune system-driven B cell clonal expansion.

Authors:  Hyunjoo Lee; Shabirul Haque; Jennifer Nieto; Joshua Trott; John K Inman; Steven McCormick; Nicholas Chiorazzi; Patricia K A Mongini
Journal:  J Immunol       Date:  2012-05-18       Impact factor: 5.422

3.  Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples.

Authors:  Maria Grazia di Iasio; Riccardo Addobbati; Oriano Radillo; Rebecca Voltan
Journal:  Invest New Drugs       Date:  2011-05-31       Impact factor: 3.850

Review 4.  miR deregulation in CLL.

Authors:  Veronica Balatti; Yuri Pekarky; Lara Rizzotto; Carlo M Croce
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

Review 5.  microRNA and cancer.

Authors:  Mengfeng Li; Jun Li; Xiaofan Ding; Mian He; Shi-Yuan Cheng
Journal:  AAPS J       Date:  2010-04-28       Impact factor: 4.009

6.  microRNA-34a is tumor suppressive in brain tumors and glioma stem cells.

Authors:  Fadila Guessous; Ying Zhang; Alex Kofman; Alessia Catania; Yunqing Li; David Schiff; Benjamin Purow; Roger Abounader
Journal:  Cell Cycle       Date:  2010-03-15       Impact factor: 4.534

7.  The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients.

Authors:  J Boysen; S Sinha; T Price-Troska; S L Warner; D J Bearss; D Viswanatha; T D Shanafelt; N E Kay; A K Ghosh
Journal:  Leukemia       Date:  2013-10-18       Impact factor: 11.528

Review 8.  The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas.

Authors:  Brian D Adams; Christine Parsons; Frank J Slack
Journal:  Expert Opin Ther Targets       Date:  2015-12-11       Impact factor: 6.902

9.  Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL.

Authors:  Miaoxia He; Li Gao; Shimin Zhang; Liyang Tao; Jianjun Wang; Jianmin Yang; Minghua Zhu
Journal:  Gastric Cancer       Date:  2013-11-14       Impact factor: 7.370

10.  Karyotype-specific microRNA signature in chronic lymphocytic leukemia.

Authors:  Rosa Visone; Laura Z Rassenti; Angelo Veronese; Cristian Taccioli; Stefan Costinean; Baltazar D Aguda; Stefano Volinia; Manuela Ferracin; Jeff Palatini; Veronica Balatti; Hansjuerg Alder; Massimo Negrini; Thomas J Kipps; Carlo M Croce
Journal:  Blood       Date:  2009-08-28       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.